Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD OTCMKTS:NURPF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$25.47-0.6%$22.85$19.69▼$28.35$4.36B0.81.67 million shs205,149 shsNURPFNeuren PharmaceuticalsC$13.46C$9.99C$7.70▼C$14.80N/AN/A808 shsN/AThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-1.12%-2.95%+22.40%+15.61%+13.66%NURPFNeuren Pharmaceuticals0.00%0.00%+58.73%+52.52%+33.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$25.47-0.6%$22.85$19.69▼$28.35$4.36B0.81.67 million shs205,149 shsNURPFNeuren PharmaceuticalsC$13.46C$9.99C$7.70▼C$14.80N/AN/A808 shsN/AThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-1.12%-2.95%+22.40%+15.61%+13.66%NURPFNeuren Pharmaceuticals0.00%0.00%+58.73%+52.52%+33.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.65Moderate Buy$32.9429.35% UpsideNURPFNeuren Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ACAD and NURPF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2026ACADACADIA Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$29.00 ➝ $36.006/30/2026ACADACADIA Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/30/2026ACADACADIA Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$29.00 ➝ $30.006/29/2026ACADACADIA Pharmaceuticals Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$37.006/29/2026ACADACADIA Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $35.006/29/2026ACADACADIA Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $36.005/8/2026ACADACADIA Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $32.005/1/2026ACADACADIA Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)(Data available from 7/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B4.07$0.87 per share29.22$7.25 per share3.51NURPFNeuren PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.2011.5829.6118.6734.30%9.61%7.07%8/4/2026 (Confirmed)NURPFNeuren PharmaceuticalsN/A-C$0.01N/AN/AN/AN/AN/AN/AN/ALatest ACAD and NURPF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026ACADACADIA Pharmaceuticals$0.05N/AN/AN/A$295.83 millionN/A5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ANURPFNeuren PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48NURPFNeuren PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%NURPFNeuren Pharmaceuticals1.74%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%NURPFNeuren PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableNURPFNeuren PharmaceuticalsN/AN/AN/ANot OptionableACAD and NURPF HeadlinesRecent News About These CompaniesNeuren Pharmaceuticals shares rocket after inching closer to EU approvalJune 30, 2026 | msn.comNeuren launches Investor Hub to bolster engagement as neurological pipeline advancesJune 29, 2026 | theglobeandmail.comNeuren Set for Major EU Milestone as EMA Backs DAYBU for Rett SyndromeJune 28, 2026 | tipranks.comNURPF Neuren Pharmaceuticals LimitedJune 17, 2026 | seekingalpha.comNeuren Issues 360,000 Unquoted Shares Under Employee Incentive SchemeJune 1, 2026 | tipranks.comNeuren Investors Back Board and CEO Options but Reject Constitution ChangesMay 27, 2026 | tipranks.comNeuren Leverages DAYBUE Windfall to Drive NNZ-2591 Phase 3 Push in Rare Neurological DisordersMay 26, 2026 | tipranks.comNeuren Advances NNZ-2591 Into Phase 3 Extension, Deepening Its Rare-Disease PipelineMay 22, 2026 | tipranks.comBell Potter Reaffirms Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)May 10, 2026 | theglobeandmail.comNeuren Updates Market on Ongoing On-Market Share Buy-BackMay 5, 2026 | tipranks.comNeuren Sets Hybrid 2026 AGM, Puts Director Re-election to Shareholder VoteApril 23, 2026 | tipranks.comNeuren Pharmaceuticals Outlines Procedures for Virtual Shareholder MeetingApril 23, 2026 | tipranks.comNeuren details 2025 progress and governance in latest annual reportApril 23, 2026 | tipranks.comNeuren Files Updated ASX Governance Appendix, Confirms Compliance With Key StandardsApril 23, 2026 | tipranks.comNeuren Updates Market on Ongoing On‑Market Share Buy‑BackApril 20, 2026 | tipranks.comNeuren Pharmaceuticals Updates Market on Ongoing Share Buy-BackApril 19, 2026 | tipranks.comNeuren Updates Market on Progress of On-Market Share Buy-BackApril 16, 2026 | tipranks.comWhy Neuren shares are rebounding on Wednesday after a brutal 2026 sell-offApril 8, 2026 | msn.comNeuren Expands Rett Syndrome Reach as DAYBUE STIX Goes Broadly U.S.-AvailableApril 7, 2026 | tipranks.comNeuren Pharmaceuticals Reports Lapse of 50,000 Conditional OptionsMarch 26, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACAD and NURPF Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$25.47 -0.16 (-0.64%) As of 11:13 AM Eastern This is a fair market value price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Neuren Pharmaceuticals OTCMKTS:NURPFC$13.46 0.00 (0.00%) As of 07/14/2026Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Has Broadcom Become Too Expensive for Its AI Story? The AI Data Center Boom Is Bigger Than One Stock—These ETFs Spread the Bet Palantir's Wild Ride: Inside the Stock Wall Street Can't Agree On Revving Up Returns: Big Banks Race Through the Rate Plateau Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
